Tertiary lymphoid structures and cancer immunotherapy
Aleix Prat shared on LinkedIn:
“Tertiary lymphoid structures (TLSs) are increasingly recognized as key players in the tumor immune microenvironment, driving adaptive immune responses and improving outcomes in cancer immunotherapy, as highlighted in this review.
Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside: Med
Authors: Jean-Philippe Guegan, Lucile Vanhersecke, Maxime Brunet, Diego Teyssonneau, Lola-Jade Palmieri, Alban Bessede,
Our own research has shown how the 14-gene IGG signature and its gene, closely related to TLSs, is strongly associated with immune fitness and overall survival in breast cancer. These findings underscore the vital role of TLSs and immune activity in shaping long-term outcomes and advancing precision oncology.
Authors: Angelats, L.Paré, C. Rubio-Perez, E. Sanfeliu, A. González, E. Seguí, G. Villacampa, M. Marín-Aguilera, S. Pernas, B. Conte, V. Albarrán-Fernández, O. Martínez-Sáez, Á. Aguirre, P. Galván, A. Fernandez-Martinez, S. Cobo, M. Rey, A. Martínez-Romero, B. Walbaum, F. Schettini, M. Vidal, W. Buckingham, M. Muñoz, B. Adamo, Y. Agrawal, S. Guedan, T. Pascual, J. Agudo, M. Grzelak, N. Borcherding, H. Heyn, A. Vivancos, J.S. Parker, P. Villagrasa, C.M. Perou, A. Prat F. Brasó-Maristany.
When cancer immune response meets longevity, the future of cancer care evolves.”
Aleix Prat is the Director of the Cancer Institute at the Hospital Clinic of Barcelona, Head of the Translational Genomics Group at IDIBAPS, and a Professor at the University of Barcelona.
He is also a Co-Founder of REVEAL GENOMICS, S.L. His work focuses on breast cancer genomics and the development of omics-based assays for clinical application. His expertise lies in breast cancer and gene expression profiling.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023